News

Press Release: Bill and Melinda Gates to receive honorary degrees from Karolinska Institutet

Press Release: Bill and Melinda Gates to receive honorary degrees from Karolinska Institutet

Press Release: Ambrilia Biopharma CEO Hans Mader Resigns

Press Release: Ambrilia Biopharma CEO Hans Mader Resigns

Press Release: Novacea to Acquire Exclusive Marketing Rights for Cancer Drug

Press Release: Novacea to Acquire Exclusive Marketing Rights for Cancer Drug

Press Release: Merck Reports Strong Financial Results for First-Quarter 2007

Press Release: Merck Reports Strong Financial Results for First-Quarter 2007

Press Release: Metabolex Raises $32 Million

Press Release: Metabolex Raises $32 Million

Press Release: NEOPHARM Announces Strategic Reassessment and Reorganization

Press Release: NEOPHARM Announces Strategic Reassessment and Reorganization

Press Release: Aranesp "145 Study" Shows No Difference in Survival in Patients with Small-Cell Lung Cancer

Press Release: Aranesp "145 Study" Shows No Difference in Survival in Patients with Small-Cell Lung Cancer

Press Release: Novartis Expands Late-stage Oncology Pipeline With AS1404

Press Release: Novartis Expands Late-stage Oncology Pipeline With AS1404

Novartis inks $890M cancer therapy deal

Earlier this week, Novartis CEO Daniel Vasella indicated Novartis would use some of the cash gained from the recent sales of two major divisions to fill the company's pipeline. Wasting no time, Novartis has inked a massive deal for the worldwide rights to Antisoma's AS1404, a lung cancer therapy currently in mid-stage testing. Novartis will pay up to $890 million for the drug. The …

Amgen breathes a sigh of relief on Aranesp results

Finally, some much-needed good news for Amgen. Dispelling fears that its anemia drug is unsafe, Amgen has release new data from a Phase III trial of Aranesp showing no difference in risk of death among patients with small-cell lung cancer. The study demonstrated a significant change in hemoglobin concentration in favor of Aranesp (a co-primary endpoint). Aranesp-treated patients also …

NeoPharm slashes jobs in restructuring

In the wake of poor trial results and demands from the FDA for additional data for its drug Cintredekin Besudotox, NeoPharm is restructuring and cutting its staff to reduce costs. Chief Medical Officer and Executive Vice President Jeffrey Sherman is stepping down, and Executive Vice President of Commercial Operations Timothy Walbert will also be leaving …

Metabolex raises $32M in fourth round

Hayward, CA-based Metabolex has raised $32 million in a Series D financing and plans to use the money to accelerate clinical testing of MBX-8025, a treatment for dyslipidemia. Additionally, the company will further the development of several preclinical programs. The round was led by MPM BioEquities and included contributions from new investors AllianceBernstein, Deerfield Management and T. Rowe Price as well as existing investors. Last year, Johnson & Johnson bought into Metabolex's …

Senate bars Medicare Part D drug negotiations

In a turn of events that will please many drug developers, a bill that allowing the federal government to negotiate the prices of drugs provided under Medicare Part D hit a setback in the Senate. Supporters of the bill have said allowing the government to negotiate prices will make the program more affordable. They've also accused special interest groups--in the form of drug companies--of using …

SPOTLIGHT: Merck reports strong Q1 results

Merck reports strong Q1 results
It appears Merck's current line-up of drugs has filled the void left by the loss of Zocor last year. The company announced strong Q1 results, with worldwide sales at $5.8 billion for the quarter--an increase of 7 percent from the first quarter of 2006. Overall, Merck's first-quarter profit jumped 12 percent, due to strong sales and money earned from product divestitures. Release

VC: Sangart gains $50M in sixth round


Sangart gains $50M in sixth round

ALSO NOTED: Novacea, KuDOS sign deal; Mader leaves CEO spot at Ambrilla; and much more...

> Novacea has signed a deal with KuDOS Pharmaceuticals (a subsidiary of AstraZeneca) for KuDOS' anti-cancer agent AQ4N, Novacea gains the rights to worldwide development and commercialization of AQ4N., which is currently in Phase I clinical trials. Release

> Chutes & Ladders: Hans J. Mader is leaving his position as President and CEO and as a member of the Board at Ambrilia …

Press Release: Stem Cell Institute President Resigns

Press Release: Stem Cell Institute President Resigns

Press Release: Iroko Pharmaceuticals Appoints John Vavricka as President and CEO

Press Release: Iroko Pharmaceuticals Appoints John Vavricka as President and CEO

Press Release: Abbott Laboratories Profit Falls; Shares Slip on Humira Concern

Press Release: Abbott Laboratories Profit Falls; Shares Slip on Humira Concern

Press Release: aTyr Pharma Completes $10.5 Million Series B Round

Press Release: aTyr Pharma Completes $10.5 Million Series B Round